Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polvitolimod + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Primmune Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PRTX007 + pembrolizumab is an investigational combination therapy being evaluated for the treatment of cancer, specifically resectable Stage III melanoma in the neoadjuvant setting. The combination consists of polvitolimod hydrochloride (PRTX007), an orally administered, systemically acting small-molecule prodrug that agonizes Toll-like receptor 7 (TLR7), and pembrolizumab (Keytruda), a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Polvitolimod is designed to selectively activate the interferon regulatory factor 7 (IRF7) pathway to drive a poly-interferon response while avoiding the pro-inflammatory NF-κB pathway. By combining innate immune activation via TLR7 agonism with adaptive immune checkpoint inhibition via PD-1 blockade, the regimen aims to enhance anti-tumor immune responses and improve pathologic response rates prior to surgical resection.
- Other names
- polvitolimod HCl + pembrolizumabpolvitolimod hydrochloride + pembrolizumabPRTX007 + pembrolizumab
02
Targets
IRF7 (Interferon regulatory factor 7)NFKB1 (NF-κB1)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)PDCD1 (Programmed cell death protein 1 receptor)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on polvitolimod + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polvitolimod + pembrolizumab.